Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for FREE.
Pacific Biosciences of California is currently working with the same analyst price targets investors have seen recently, with no changes reported. With no fresh analyst commentary accompanying this update, the market narrative around those targets is being shaped largely by existing views and new data points from the company itself. In this article, you will see how to track these steady targets, how to read between the lines when commentary is quiet, and how to stay on top of the ways the narrative may evolve from here.
Wall Street’s queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab’s valuation page.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there’s more to the story. Head to the Simply Wall St Community to discover more perspectives!
We’ve flagged 2 risks for Pacific Biosciences of California. See which could impact your investment.
How This Changes the Fair Value For Pacific Biosciences of California
Fair value estimate, no change reported
Revenue growth assumptions, no change reported
Net profit margin assumptions, no change reported
P/E ratio input, no change reported
Discount rate used in valuation, no change reported
Never Miss an Update: Follow The Narrative
Narratives connect Pacific Biosciences of California’s business story to forward looking expectations and fair value estimates. They refresh when new company data, news, or forecasts are added so you can see how the story is evolving.
Head over to the Simply Wall St Community and follow the Narrative on Pacific Biosciences of California to stay up to date on:
How new product updates, clinical collaborations, or technology milestones might influence future expectations for the business.
What changing competitive, regulatory, or funding conditions could mean for the company’s ability to execute its plans.
The key operational and financing risks that community analysts are watching most closely for this stock.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Read More: How The Pacific Biosciences (PACB) Investment Narrative Is Evolving Without
